OTTAWA--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) ("Avivagen"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the Second quarter of 2023.
"The Special Committee continues to examine all potential alternatives, including a strategic sale, in whole or in part, of the company", said Kym Anthony, Avivagen CEO. "To date, Avivagen has received numerous responses from firms wishing to engage in preliminary discussions regarding such alternatives".
Second Quarter April 30, 2023, Financial Results
The Company's unaudited Financial Statements for the second quarter ended April 30, 2023, and the accompanying Management's Discussion and Analysis have been filed on the System for Electronic Document Analysis and Retrieval and are available via its website (). The financial information for the second quarter ended April 30, 2023, should be read in conjunction with the Company's unaudited Financial Statements as well as its Management's Discussion and Analysis for the second quarter ended April 30, 2023
The Company reported net revenues of $77,683 and a comprehensive loss of $(1,244,829) for the three-month period ended April 30, 2023. This compares to revenues of $88,438 and a comprehensive loss of $(1,303,677) in the three-month period ended April 30, 2022.
For the six-month period ended April 30, 2023, the Company reported net revenues of $143,722 and a comprehensive loss of $(2,398,759). This compares to revenues of $359,595 and a comprehensive loss of $(2,856,529) in the six-month period ended April 30, 2022.
As of April 30, 2023, the Company reported total assets of $324,686 (current assets of $266,140), total liabilities of $8,633,272, and shareholders' deficit of $(8,308,586).
About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta Technology and OxC-beta Livestock
Avivagen's OxC-beta technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function, the technology provides a non-antibiotic means of promoting health and growth. OxC- beta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Mexico, Philippines, Taiwan China, New Zealand, Thailand, Australia and Malaysia. OxC-beta has been fed to over 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.
Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
加拿大渥太華--(BUSINESS WIRE)--Avivagen Inc.(TSXV:VIV)("Avivagen")是一家專注於開發和商業化牲畜、伴侶動物和人類應用產品的生命科學公司,安全地提高飼料攝入量並支持免疫功能,從而支持總體健康和表現,日前宣佈其2023年第二季度未經審計的財務業績。
Avivagen首席執行官Kym Anthony表示:"特別委員會將繼續研究所有潛在的替代方案,包括對公司進行全部或部分的戰略出售"。"到目前爲止,Avivagen已經收到了許多希望就此類替代方案進行初步討論的公司的回覆"。
2023年4月30日第二季度財務業績
公司截至2023年4月30日的第二季度未經審計的財務報表以及隨附的管理層討論與分析已經在電子文件分析與檢索系統上備案,並可通過其網站查閱。截至2023年4月30日的第二季度的財務信息應與公司未經審計的財務報表以及截至2023年4月30日的第二季度的管理層討論和分析一起閱讀。
公司報告截至2023年4月30日的三個月期間,淨收入爲77,683美元,綜合虧損爲(1,244,829)美元。相比之下,截至2022年4月30日的三個月期間的收入爲88,438美元,全面虧損爲(1,303,677)美元。
在截至2023年4月30日的六個月期間,公司報告的淨收入爲143,722美元,綜合虧損爲(2,398,759)美元。相比之下,截至2022年4月30日的六個月期間,收入爲359,595美元,綜合損失爲(2,856,529)美元。
截至2023年4月30日,公司報告的總資產爲324,686美元(流動資產爲266,140美元),總負債爲8,633,272美元,股東赤字爲(8,308,586)美元。
關於Avivagen
Avivagen是一家生命科學公司,專注於爲牲畜、伴侶動物和人類應用開發和商業化產品,通過安全地支持免疫功能,促進總體健康和表現。它是一家在多倫多證券交易所創業板上市的上市公司,股票代碼爲VIV,總部設在加拿大渥太華,是加拿大國家研究委員會的合作機構。該網站的內容明確地沒有被納入本新聞稿的參考。
關於OxC-beta技術和OxC-beta畜牧業
Avivagen的OxC-beta技術源於安維根對β-胡蘿蔔素和其他類胡蘿蔔素的發現,這些化合物使某些水果和蔬菜具有明亮的色彩。通過對免疫功能的支持,該技術提供了一種非抗生素的手段來促進健康和生長。OxC-β家畜是一種專利產品,被證明是一種有效和經濟的替代品,可以替代通常添加到家畜飼料中的抗生素。該產品目前可在美國、墨西哥、菲律賓、中國臺灣、新西蘭、泰國、澳大利亞和馬來西亞銷售。OxC-beta已經被餵給了超過4660萬頭食用動物(家禽、豬和乳牛)、133,820只狗和4000人。
安維根的OxC-beta家畜產品是安全、有效的,並且可以實現全球取消所有飼料中抗生素作爲生長促進劑的任務。許多使用OxC-beta牲畜產品的家禽和豬的國際牲畜試驗證明,該產品的性能與飼料中的抗生素一樣好,有時在某些方面甚至比抗生素更好。